Pre-Infusion Host-Marrow Vulnerability in CD19- and BCMA-Directed CAR T-Cell Therapy: Clonal Hematopoiesis, Hematotoxicity, and Therapy-Related Myeloid Neoplasia
{{output}}
CD19- and B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T-cell) therapies have improved outcomes in relapsed or refractory B-cell lymphoid malignancies and multiple myeloma, but late hematologic complications are increasingly ... ...
